DUBLIN--(BUSINESS WIRE)--The "Liver Fibrosis - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
This 'Liver Fibrosis- Epidemiology Forecast-2032' report delivers an in-depth understanding of the Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Liver Fibrosis Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Liver Fibrosis, Severity-specific Diagnosed Cases of Non Alcoholic Steatohepatitis (NASH), Total Diagnosed Prevalent cases of Liver Fibrosis in NASH, in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan, from 2019 to 2032.
Liver Fibrosis Detailed Epidemiology Segmentation
- In the assessment done by the publisher, the estimated total diagnosed prevalent cases of Liver Fibrosis in the 7MM were 19,126,579 in 2021.
- The highest total diagnosed prevalent cases of Liver Fibrosis were accounted by the US in 2021 (9,488,135 cases), which are expected to show a rise in the future.
- Among the European countries, Germany had the highest diagnosed prevalent cases of Liver Fibrosis with 1,641,162 cases, followed by Italy, which had prevalent population of 1,532,651 in 2021. On the other hand, Spain had the lowest prevalent population (1,307,582 cases).
- Japan had 2,299,149 total diagnosed prevalent cases of Liver Fibrosis in 2021, accounting for approximately 12% in 7MM.
Scope of the Report
- The report covers the descriptive overview of Liver Fibrosis, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan.
- The report assesses the disease risk and burden of Liver Fibrosis.
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
Report Highlights
- 11-Year Forecast of Liver Fibrosis
- 7MM Coverage
- Total Diagnosed Prevalent Cases of Liver Fibrosis
- Severity-specific Diagnosed Prevalent Cases of NASH
- Diagnosed Prevalent Cases of NASH-specific Liver Fibrosis
Key Assessments
- Patient Segmentation
- Patient Segmentation based on Severity-specific
- Patient Segmentation based on NASH-specific
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Liver Fibrosis Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of Liver Fibrosis in 2019
3.2. Patient Share (%) Distribution of Liver Fibrosis in 2032
4. Executive Summary of Liver Fibrosis
5. Disease Background and Overview: Liver Fibrosis
5.1. Introduction of Liver Fibrosis
5.2. Fibrogenesis in Liver Fibrosis
5.3. Etiology of Liver Fibrosis
5.3.1. Metabolic disorders: Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
5.3.2. Genetic disorders
5.3.3. Alcohol
5.3.4. Drugs
5.3.5. Cholestasis
5.3.6. Viral hepatitis
5.3.7. Parasitic infections
5.3.8. Cryptogenic causes
5.4. Pathophysiology of Liver Fibrosis
5.4.1. Cell types in liver fibrosis
5.5. Diagnostic Approach for Liver Fibrosis
5.5.1. General approach to evaluate liver fibrosis
5.5.2. Liver biopsy and histologic assessment of the liver
5.5.3. Classification of liver histology
5.5.4. Indirect markers of fibrosis
5.5.5. Direct markers of fibrosis
5.5.6. Radiologic Modalities to Estimate Fibrosis
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology of Epidemiology
6.3. Assumptions and Rationale: 7MM
6.3.1. United States
6.3.2. EU-5 Countries
6.3.3. Japan
6.4. Total Diagnosed Prevalent cases of Liver Fibrosis in the 7MM
6.5. The United States
6.5.1. Total diagnosed prevalent cases of Liver fibrosis in the United States
6.5.2. Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in the United States
6.5.3. Total Diagnosed Prevalent cases of Liver fibrosis in NASH in the United States
6.6. Major Five European Countries
6.7. Japan
7. Patient Journey
8. KOL Views
9. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/vt7dr7
